Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Classifica tra le azioni #93
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and... Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Prezzo delle azioni
$137.21
Capitalizzazione di mercato
$170.34B
Variazione (1 giorno)
-2.76%
Variazione (1 anno)
28.14%
Paese
US
Scambia Gilead Sciences, Inc. (GILD)

Categoria

Ricavi di Gilead Sciences, Inc. (GILD)
Ricavi nel Dec 2025 TTM: $29.44B
Secondo gli ultimi rapporti finanziari di Gilead Sciences, Inc., i ricavi attuali dell'azienda (TTM) sono pari a $29.44B. Nel 2024, l'azienda ha registrato ricavi di $28.75B un aumento rispetto a i ricavi dell'anno 2023, che erano pari a $27.12B. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Gilead Sciences, Inc. da 2000 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) $29.44B 0.00%
2025 $29.44B 2.40%
2024 $28.75B 6.04%
2023 $27.12B -0.60%
2022 $27.28B -0.09%
2021 $27.31B 10.60%
2020 $24.69B 9.98%
2019 $22.45B 1.46%
2018 $22.13B -15.24%
2017 $26.11B -14.09%
2016 $30.39B -6.89%
2015 $32.64B 31.13%
2014 $24.89B 122.19%
2013 $11.20B 15.46%
2012 $9.70B 15.70%
2011 $8.39B 5.48%
2010 $7.95B 13.38%
2009 $7.01B 31.40%
2008 $5.34B 26.14%
2007 $4.23B 39.78%
2006 $3.03B 49.19%
2005 $2.03B 53.13%
2004 $1.32B 52.63%
2003 $867.86M 85.92%
2002 $466.79M 99.68%
2001 $233.77M 19.54%
2000 $195.56M 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
$65.18B 121.38%
US
$58.74B 99.51%
GB
$94.19B 219.93%
US
$61.16B 107.73%
US
$56.15B 90.71%
CH